miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. - Wikidata - wikimedia - TriplyDB

miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.

miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.

http://www.wikidata.org/entity/Q53278601

about

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression MicroRNAs targeting prostate cancer stem cells MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension MicroRNA‑328 directly targets p21‑activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity Getting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle.MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer.MicroRNA-143 inhibits tumorigenesis in hepatocellular carcinoma by downregulating GATA6.Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1 MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer.Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression miR-105 inhibits prostate tumour growth by suppressing CDK6 levels Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers.Circulating microRNAs in patients with active pulmonary tuberculosis.Competitive interactions of cancer cells and normal cells via secretory microRNAs Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1.Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion.Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism USP2a alters chemotherapeutic response by modulating redox.microRNA and gene networks in human pancreatic cancer miR-143 is associated with proliferation and apoptosis involving ERK5 in HeLa cells MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.The proto-oncogene KRAS is targeted by miR-200c.Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics.Recent updates on the role of microRNAs in prostate cancer.MicroRNAs in pancreatic cancer metabolism.MicroRNAs as putative mediators of treatment response in prostate cancer.

P2860

Q26769599-E2F607F2-194C-4FA2-95C7-EAFF3135575F Q26783563-B1ABE865-5E38-480C-83C7-2DA763D9CBB0 Q26796592-B8B2BB95-1FE9-4F24-BF8B-00A97A860ABD Q28081039-A59382B5-AA1C-40BD-A80D-A0EEA88BA246 Q28114802-2EC5D1DA-0A69-4860-B883-181D9E04D7B7 Q28268506-7E819AA5-95FC-4A47-8E26-1AFCA27CAF4E Q33351113-E7C38183-D546-4886-B664-EF674A4F3E6A Q33599411-EE430CE6-75AF-4DAE-A353-FAF7C686F91C Q33688159-E1351B2D-23B9-48A8-B2CF-114C28C22442 Q33744249-4BCF9718-694F-4082-B432-4FB547C80F6A Q34133268-24C1ACD0-A133-4D12-B4A8-B62DC59A88B8 Q34154782-207C77B7-2038-4D3E-A097-782261BB7FED Q34212106-D7171E22-BE3E-4BD9-B750-2381E07B7A3A Q34448246-F7036A95-189D-450B-8629-42A097A76985 Q34577512-2764E3E6-7335-4413-A58F-9B37269C2ED4 Q34947109-53F23201-9EF2-4A92-9DE0-6EAB9B17F41D Q35109229-108665F2-6A58-4718-A427-23B42BBFF897 Q35145657-709997FC-1735-4878-A02A-79AFCC8F94D6 Q35510445-5F18624D-53EA-4D94-BC81-A11D59B0F2E1 Q35598890-4EFE5000-36FC-4A07-A357-6BA8209F2488 Q35668889-07B695F1-6421-4427-957D-6BD5B6C48140 Q35755238-56F334D5-9CBE-403B-812A-F53D6FF5D2BB Q35832689-5C6285D2-1C7C-4B1F-8F4D-D5B38C8FB97C Q35904981-46EA204C-3B89-4E26-B25F-68D648A2E04E Q36375212-AA007609-F9B2-4F4F-BBB7-A4213C84BD10 Q36545734-883A1D80-499E-4DEC-93C6-EC50DE6B1F8F Q36557814-611D84D5-749D-4B22-A54F-343CEEBE91CF Q36962611-09E5C156-70EC-404E-81B2-2E8E6F0E4EEA Q37058847-7C896065-6B4D-40EC-B280-785CB797EFE1 Q37211956-32BA6C3E-B670-44BD-AFEB-7425C9A2BAE4 Q37229344-086B38E7-450D-4669-8003-F5446D12862F Q37287591-555EF50A-4E6B-4F58-A8B4-A7FE6A6BE754 Q37565167-616D65D8-D870-47B7-B55C-7FEE04F1CB1C Q37649657-A8F5FF0E-896B-409D-A221-264006C80949 Q37669900-5D49A902-CF4C-4C7E-957C-6AB45A83C4A6 Q37696230-5D7AF915-006D-41C3-BC4D-EC997323E929 Q37983956-BB0E434D-3049-41B9-AC12-E70D70E2B122 Q37993624-41A83B17-8A0A-4A77-AC10-9A0F6A011ECC Q38003048-B7E9CBA6-1A1C-4B3C-8CD2-99E6E692C6E5 Q38011943-F7845AB4-F432-493D-840A-5E1DE34EFA08

P2860

miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.

http://www.wikidata.org/entity/Q53278601

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

miR-143 decreases prostate can ...... l through suppression of KRAS.

@en

miR-143 decreases prostate can ...... l through suppression of KRAS.

@nl

type

label

miR-143 decreases prostate can ...... l through suppression of KRAS.

@en

miR-143 decreases prostate can ...... l through suppression of KRAS.

@nl

prefLabel

miR-143 decreases prostate can ...... l through suppression of KRAS.

@en

miR-143 decreases prostate can ...... l through suppression of KRAS.

@nl

P1433

Q53278601-57282B44-B61C-438C-BAAF-C70EB451B291

P1476

Q53278601-0B58A8B8-6C45-420E-AB0E-5D97B424426B

P2093

Q53278601-0D887496-5358-467D-953E-FDC6D96EBDBB

Q53278601-10B2B54C-AB65-40CD-AF94-C5785951ED21

Q53278601-2772074F-83AF-4667-A37A-2EFC3EA5E062

Q53278601-35895338-149F-495C-82B0-685203CE2ACF

Q53278601-38812686-5AD1-4CB3-8534-2B5A1DB72030

Q53278601-46E18A26-8E36-4C34-A498-EC1D30C9C983

Q53278601-60B34B1A-A256-4904-94AC-BD390BDC58CB

Q53278601-81887CAC-2935-41B6-9AD2-F35CB43623FA

Q53278601-B0AA1A54-2FA5-408A-BBF0-4096C1AFE2E1

Q53278601-BC045102-3A88-4CDE-A799-4CEF5AAFEAFA

P2860

Q53278601-03C2745D-0F73-41A3-9ACD-4DC272DC5E23

Q53278601-080B6254-39E6-4343-9227-9B20BA657F27

Q53278601-088207D9-CA6B-4BDF-9EA9-4F6775EF65EB

Q53278601-08F77F1F-834C-4973-A0A9-EA799DA947A7

Q53278601-23B940BA-3712-4F57-90E6-E5F5B30D0838

Q53278601-2EF21D7C-B13A-4347-84C9-0E452E7F612F

Q53278601-40588E5E-88C8-40AE-8BEB-2FC0A0EEE84F

Q53278601-489D4634-035A-4803-9729-9292B4567756

Q53278601-542898DE-114D-4CCA-8148-6407C3FCC7DE

Q53278601-841A09A2-641E-4492-B7DE-FEFD2C530FE1

P2888

Q53278601-8490627A-C856-4475-B09A-3E5788EF472B

P304

Q53278601-FFD298A8-35AF-4F84-8E12-92C3AEF24514

P31

Q53278601-83C800D7-A513-4437-B10B-AD4F7D59DA4F

P356

Q53278601-CA44D15E-D2D0-4AB2-B608-FBB89843D1E8

P433

Q53278601-4BDA4C6C-985E-4A81-84D1-7DEC783C81A2

P478

Q53278601-BC0D4E51-D334-4BD8-A3FA-B99B85C1759C

P577

Q53278601-FF2669F9-3505-4F09-A793-545936AB190B

P5875

Q53278601-4C1CFFBF-C7C0-4BA3-BA6C-6D8C7C5403E8

P698

Q53278601-4588E268-8FDB-4F73-A652-1FD68BD20867

P356

S11010-010-0700-6

P1433

Molecular and Cellular Biochemistry

P1476

miR-143 decreases prostate can ...... l through suppression of KRAS.

@en

P2093

Bin Xu

http://www.w3.org/2001/XMLSchema#string

Deyao Wu

http://www.w3.org/2001/XMLSchema#string

Hongfei Wu

http://www.w3.org/2001/XMLSchema#string

Jun Tao

http://www.w3.org/2001/XMLSchema#string

Lixin Hua

http://www.w3.org/2001/XMLSchema#string

Ninghan Feng

http://www.w3.org/2001/XMLSchema#string

Pengchao Li

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xiangxiang Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaobing Niu

http://www.w3.org/2001/XMLSchema#string

P2860

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice

A uniform system for microRNA annotation

A microRNA expression signature of human solid tumors defines cancer gene targets

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

Most mammalian mRNAs are conserved targets of microRNAs

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets

Cancer statistics, 2009

The development of androgen-independent prostate cancer

An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues

P2888

s11010-010-0700-6

P304

207-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11010-010-0700-6

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49720583

http://www.w3.org/2001/XMLSchema#string

P698

21197560

http://www.w3.org/2001/XMLSchema#string